普伦巴根可以缓解与肥胖相关的喘:向炎症,氧化应激和AMPK通路
Lijie Zhang1, Dongxue Liang2, Linlin Liu2
1Second Ward of Respiratory Department, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, People's Republic of China.
Immunity, inflammation and disease
|September 29, 2023
概括
普伦巴根 (PLB) 通过减少呼吸道炎症和氧化应激,可以治疗与肥胖相关的喘. 这项研究发现,PLB在肥胖的喘小鼠中减轻了症状,这表明了治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 与肥胖相关的喘表现出严重的症状和对标准治疗的耐药性.
- 巴 (PLB) 以其健康益处而闻名,但它对与肥胖相关的喘的影响尚未被探索.
研究的目的:
- 调查plumbagin (PLB) 在改善与肥胖相关的喘方面的潜力.
主要方法:
- 给小鼠提供高脂肪饮食 (HFD) 来诱导肥胖,然后对卵蛋白 (OVA) 进行敏感和挑战,以模拟喘.
- 治疗包括每天内内注射PLB.
- 肺组织和支气管洗液 (BALF) 分析了炎症标志物和氧化应激.
主要成果:
- 在喘小鼠中,HFD加剧了呼吸道炎症,埃索诺菲尔数量,炎症性细胞因子 (IL-4,IL-5,eotaxin) 和氧化应激.
- PLB治疗减少了这些炎症标志物和氧化应激.
- 此外,PLB还恢复了腺单酸盐激活蛋白激酶 (AMPK) 酸化,这种酸化在HFD下降.
结论:
- 高脂肪饮食 (HFD) 在喘中加剧炎症和氧化应激.
- 巴丁 (PLB) 缓解了这些情况,并激活了AMPK通路.
- PLB显示为潜在的治疗肥胖相关喘的前景.
相关概念视频
Asthma: Pathogenesis and Management
433
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
433
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
326
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
326
Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K


